Latest

Paul Perreault: The Global CEO

Pharm Exec talks with CSL's top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

Specialty Product Launch Insights

Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.

Specialty Pharma’s Move to Mainstream

While definitions for “specialty drug” vary, this once-niche treatment market may be poised to steer the future of prescription medicine and patient care.

Beyond Big Data: Meeting the Specialty Marketing Challenge

With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach.

Pharm Exec Video

Behind the Scenes with Kallyope’s Nancy Thornberry

A sneak peek at Pharm Exec's August cover shoot with the New York City-based biotech CEO.

Why One Korean Biotech Picked New Jersey for U.S. Headquarters

New Jersey is still a top pick for companies when it comes to pharma.

Pharm Exec Talks Partnerships with Sanofi

Hear what Sanofi looks for when they decide to form a partnership with another company.

New & Noteworthy

Specialty Focus: Tackling Rare Mutation in CF

How one nonprofit and its out-front leader are joining forces with industry to advance a new personalized medicine approach for cystic fibrosis patients with nonsense mutations.

The ‘Spare-No-Expense’ Alternative

How low-cost drugs can succeed in the specialty pharmacy channel, by Charlie Bell.

Aligning Tactics with the Goals of Value-Based Care

The marketing challenge for pharmaceutical companies has now shifted to "How can we successfully and cost-effectively assist providers in orchestrating better care?" William Febbo reports.

Five Features to Ensure Lab-ready Buildings

A list of five essential features a building must have in order to be considered lab-ready.

Sales & Marketing

Beyond Big Data: Meeting the Specialty Marketing Challenge

With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach.

Senate Spending Bills Give Minor Boost to FDA, Seek Price Disclosures in Ads

The Senate has approved several multi-agency budget bills for the coming fiscal year that boost funding for FDA and the NIH – and include a contentious provision that requires biopharma companies to disclose product prices in direct-to consumer advertising.

States Expand Transparency & Disclosure Requirements

Just as biopharma companies are mastering the complexities of the five-year-old federal Open Payments program, state governments are enacting a host of additional marketing and disclosure rules and restrictions on industry interactions with HCPs.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Small Biotechs Gain As the Span of Clinical Trial Outsourcing Grows

Small biotech companies benefit more from partnering with CROs rather than hiring a chief medical officer.

Building Healthcare's "Ground Truth" with AI

For pharma leaders, AI can bring about a new reality of seeing a multitude of possible paths, forecasting the interplay of multi-dimensional trends, and charting patient journeys that are based on reality, writes Aswin Chandrakantan.

Specialty Supply Chain Decisions

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

Biosimilars Battles Heat Up

With the rise in industry programs for developing biosimilars, tensions are high as innovator firms back strategies that appear designed to delay competition. Jill Wechsler reports.

Interviews

Paul Perreault: The Global CEO

Pharm Exec talks with CSL's top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

Close to the Action: Dr. José Luis Cabero, CEO, AELIX Therapeutics

Pharm Exec talks to AELIX Therapeutics' Dr. José Luis Cabero about how the career and country shift he made a decade ago have motivated and sustained a new direction in his career.

Navigating the Complex Reimbursement and Policy Landscape of Healthcare Access

Tommy Bramley and Kristine Flemister discuss how stakeholders can better help patients and providers navigate barriers around access and affordability in a complex healthcare environment.

Regulatory

Biosimilars Battles Heat Up

With the rise in industry programs for developing biosimilars, tensions are high as innovator firms back strategies that appear designed to delay competition. Jill Wechsler reports.

Quality Failures at Foreign Manufacturers Prompt Warnings and Recalls

A wave of potentially impure drugs and APIs from China, India, and other foreign firms has prompted recalls and FDA warning letters.

Senate Spending Bills Give Minor Boost to FDA, Seek Price Disclosures in Ads

The Senate has approved several multi-agency budget bills for the coming fiscal year that boost funding for FDA and the NIH – and include a contentious provision that requires biopharma companies to disclose product prices in direct-to consumer advertising.

From the Editor

Specialty Supply Chain Decisions

In today’s drug development environment, there is no doubt that supply chain decisions are paramount in a product launch strategy, writes Lisa Henderson.

From Science to Success

A common thread in our exploration of "Emerging Biopharma" is that these companies need to be those that look beyond pure discovery—and put equal effort into the pivot to potential commercialization.

lorem ipsum